Valuation: Aquestive Therapeutics, Inc.

Market Cap 531M 461M 432M 393M 740M 50.61B 752M 5.08B 1.98B 25.34B 1.99B 1.95B 84.65B P/E 2026 *
-9.06x
P/E 2027 * -9.99x
Enterprise Value 453M 393M 368M 336M 631M 43.17B 641M 4.34B 1.69B 21.62B 1.7B 1.66B 72.21B EV / Sales 2026 *
8.93x
EV / Sales 2027 * 7.34x
Free-Float
96.94%
Yield 2026 *
-
Yield 2027 * -
1 day-4.08%
1 week+13.10%
Current month+14.48%
1 month+2.67%
3 months-2.53%
6 months+10.73%
Current year-34.52%
1 week 3.76
Extreme 3.76
4.69
1 month 3.56
Extreme 3.56
4.69
Current year 2.93
Extreme 2.93
6.59
1 year 2.93
Extreme 2.93
7.55
3 years 1.25
Extreme 1.2514
7.55
5 years 0.62
Extreme 0.618
7.55
10 years 0.62
Extreme 0.618
20.7
Manager TitleAgeSince
Chief Executive Officer 50 2022-05-16
Director of Finance/CFO 67 2020-12-30
Compliance Officer - 2026-04-01
Director TitleAgeSince
Chairman 72 2024-03-31
Director/Board Member 60 2003-12-31
Director/Board Member 50 2022-05-16
Date Insider Type Main position Quantity % Market Cap.
7/16/26 Sell

Chief Executive Officer

-20,369 0.0162%
3/9/26 Free

General Counsel

200,311 0.1642%
3/9/26 Other

Chief Operating Officer

168,291 0.1379%
Change 5-day change 1-year change 3-year change Capi.($)
-4.08%+13.10%+9.59%+118.04% 553M
+0.43%+9.38%+92.10%+130.99% 1,083B
+0.41%+2.33%+50.07%+50.05% 626B
-0.53%+2.03%+25.23%+63.46% 442B
-0.92%+2.18%+48.40%+37.85% 363B
-1.32%-0.32%+29.35%+36.81% 295B
-1.20%-0.32%+6.03%+6.09% 248B
+0.45%+6.71%+45.98%+58.54% 224B
-2.51%-2.63%-7.16%-51.74% 210B
+0.07%+0.46%+12.78%+69.84% 168B
Average -0.96%+4.38%+31.24%+51.99% 365.97B
Weighted average by Cap. -0.37%+4.29%+49.44%+65.97%

Financials

2026 *2027 *
Net sales 50.73M 44.02M 41.27M 37.6M 70.73M 4.84B 71.86M 486M 189M 2.42B 190M 186M 8.09B 72.35M 62.77M 58.85M 53.62M 101M 6.9B 102M 692M 270M 3.45B 272M 266M 11.53B
Net income -63.5M -55.1M -51.66M -47.06M -88.53M -6.05B -89.94M -608M -237M -3.03B -238M -233M -10.12B -52.01M -45.13M -42.31M -38.55M -72.51M -4.96B -73.66M -498M -194M -2.48B -195M -191M -8.29B
Net Debt -78M -67.68M -63.45M -57.81M -109M -7.43B -110M -747M -291M -3.72B -293M -286M -12.44B -
Logo Aquestive Therapeutics, Inc.
Aquestive Therapeutics, Inc. is a pharmaceutical company. The Company is engaged in developing orally administered and topical gel products to deliver complex molecules, providing novel alternatives to invasive and inconvenient standard of care therapies. It has four commercialized products marketed by the Company’s licensees in the United States and around the world and is the manufacturer of these licensed products. The Company also collaborates with pharmaceutical companies to bring new molecules to market using proprietary technologies, including PharmFilm, and has proven drug development and commercialization capabilities. The Company is advancing a late-stage proprietary product candidate for the treatment of severe allergic reactions, including anaphylaxis, and an early-stage epinephrine prodrug topical gel product candidate for various possible dermatology conditions. Its portfolio includes Anaphylm, AQST-108, Libervant, Suboxone, and Emylif.
Employees
147
Date Price Change Volume
26-08-12 US$4.230 -4.08% 9,094,296
26-08-11 US$4.410 +2.80% 6,495,034
26-08-10 US$4.290 +8.88% 7,295,514
26-08-07 US$3.940 +0.51% 1,860,430
26-08-06 US$3.920 +4.39% 1,536,412
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
4.410USD
Average target price
9.222USD
Spread / Average Target
+109.12%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AQST Stock